Page last updated: 2024-09-04

cyc 682 and Breast Cancer

cyc 682 has been researched along with Breast Cancer in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baker, SD; Carducci, MA; Dees, EC; Donehower, R; Gilbert, J	1
Hanaoka, K; Hisaoka, M; Ikeda, T; Iwabuchi, H; Kaneko, M; Kobayashi, T; Kurakata, S; Matsuda, A; Mitsuhashi, Y; Miura, S; Nakagawa, A; Nomura, T; Sasaki, T; Shibayama, T; Suzuki, M; Tanaka, K; Tanzawa, F; Tomida, A; Tsuruo, T; Wataya, Y	1

Trials

1 trial(s) available for cyc 682 and Breast Cancer

Article	Year
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Investigational new drugs, 2006, Volume: 24, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleosides; Breast Neoplasms; Colorectal Neoplasms; Cytosine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prodrugs; Treatment Failure; Treatment Outcome	2006

Article

Year

A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.

Investigational new drugs, 2006, Volume: 24, Issue:6

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleosides; Breast Neoplasms; Colorectal Neoplasms; Cytosine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prodrugs; Treatment Failure; Treatment Outcome

2006

Other Studies

1 other study(ies) available for cyc 682 and Breast Cancer

Article	Year
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). International journal of cancer, 1999, Jul-19, Volume: 82, Issue:2 Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformation; Breast Neoplasms; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; KB Cells; Leukemia P388; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Mitomycin; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Rats, Nude; Specific Pathogen-Free Organisms; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine	1999

Article

Year

Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).

International journal of cancer, 1999, Jul-19, Volume: 82, Issue:2

Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformation; Breast Neoplasms; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; KB Cells; Leukemia P388; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Mitomycin; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Rats, Nude; Specific Pathogen-Free Organisms; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine

1999